$130.64
0.52% today
Nasdaq, Apr 03, 05:14 pm CET
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Biogen Target price 2025 - Analyst rating & recommendation

Biogen Classifications & Recommendation:

Buy
47%
Hold
53%

Biogen Price Target

Target Price $194.25
Price $131.32
Potential 47.92%
Number of Estimates 28
28 Analysts have issued a price target Biogen 2026 . The average Biogen target price is $194.25. This is 47.92% higher than the current stock price. The highest price target is $342.00 160.43% , the lowest is $135.00 2.80% .
A rating was issued by 36 analysts: 17 Analysts recommend Biogen to buy, 19 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Biogen stock has an average upside potential 2026 of 47.92% . Most analysts recommend the Biogen stock at Hold.

Sales and Margin forecast 2025, 2026 to 2029


Dec '24 2025
Estimates
Revenue Billion $ 9.27 9.20
1.60% 0.75%
EBITDA Margin 30.19% 36.68%
33.71% 21.51%
Net Margin 17.61% 20.20%
42.68% 14.73%

31 Analysts have issued a sales forecast Biogen 2025 . The average Biogen sales estimate is $9.2b . This is 0.75% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $9.9b 6.84% , the lowest is $9.0b 3.20% .

This results in the following potential growth metrics:

Revenue Estimates

2024 $9.3b 1.60%
2025 $9.2b 0.75%
2026 $9.1b 1.05%
2027 $9.2b 1.51%
2028 $9.4b 1.72%
2029 $9.4b 0.26%

11 Analysts have issued an Biogen EBITDA forecast 2025. The average Biogen EBITDA estimate is $3.4b . This is 20.60% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $3.8b 37.52% , the lowest is $2.8b 1.28% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $2.8b 31.57%
2025 $3.4b 20.60%
2026 $3.3b 2.78%
2027 $3.4b 4.23%
2028 $3.9b 15.21%
2029 $4.3b 10.28%

EBITDA Margin

2024 30.19% 33.71%
2025 36.68% 21.51%
2026 36.04% 1.74%
2027 37.00% 2.66%
2028 41.91% 13.27%
2029 46.33% 10.55%

11 Biogen Analysts have issued a net profit forecast 2025. The average Biogen net profit estimate is $1.9b . This is 13.99% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.3b 40.25% , the lowest is $1.5b 10.91% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $1.6b 40.40%
2025 $1.9b 13.89%
2026 $2.2b 16.10%
2027 $2.3b 6.84%
2028 $2.6b 12.86%
2029 $2.7b 2.00%

Net Margin

2024 17.61% 42.68%
2025 20.20% 14.73%
2026 23.70% 17.33%
2027 24.95% 5.27%
2028 27.68% 10.94%
2029 28.31% 2.28%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029


Dec '24 2025
Estimates
Earnings Per Share $ 11.19 12.74
40.40% 13.85%
P/E 10.30
EV/Sales 2.56

11 Analysts have issued a Biogen forecast for earnings per share. The average Biogen EPS is $12.74 . This is 13.95% higher than earnings per share in the financial year 2024. The highest EPS forecast is $15.68 40.25% , the lowest is $9.96 10.91% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $11.19 40.40%
2025 $12.74 13.85%
2026 $14.80 16.17%
2027 $15.81 6.82%
2028 $17.84 12.84%
2029 $18.20 2.02%

P/E ratio

Current 11.74 56.55%
2025 10.30 12.27%
2026 8.88 13.79%
2027 8.31 6.42%
2028 7.36 11.43%
2029 7.22 1.90%

Based on analysts' sales estimates for 2025, the Biogen stock is valued at an EV/Sales of 2.56 and an P/S ratio of 2.09 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.54 36.66%
2025 2.56 0.87%
2026 2.59 1.07%
2027 2.55 1.49%
2028 2.51 1.70%
2029 2.51 0.26%

P/S ratio

Current 2.07 37.68%
2025 2.09 0.76%
2026 2.11 1.06%
2027 2.08 1.49%
2028 2.05 1.70%
2029 2.05 0.26%

Current Biogen Upgrades & Downgrades

Analyst Rating Action Date
Piper Sandler
Neutral
Neutral
Unchanged Feb 18 2025
Morgan Stanley
Equal-Weight
Equal-Weight
Unchanged Feb 13 2025
HC Wainwright & Co.
Buy
Buy
Unchanged Feb 13 2025
Citigroup
Neutral
Neutral
Unchanged Feb 13 2025
BMO Capital
Market Perform
Market Perform
Unchanged Feb 13 2025
Canaccord Genuity
Buy
Buy
Unchanged Feb 13 2025
Goldman Sachs
Buy
Buy
Unchanged Feb 13 2025
Analyst Rating Date
Unchanged
Piper Sandler:
Neutral
Neutral
Feb 18 2025
Unchanged
Morgan Stanley:
Equal-Weight
Equal-Weight
Feb 13 2025
Unchanged
HC Wainwright & Co.:
Buy
Buy
Feb 13 2025
Unchanged
Citigroup:
Neutral
Neutral
Feb 13 2025
Unchanged
BMO Capital:
Market Perform
Market Perform
Feb 13 2025
Unchanged
Canaccord Genuity:
Buy
Buy
Feb 13 2025
Unchanged
Goldman Sachs:
Buy
Buy
Feb 13 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today